Author Archives: admin


Stem Cell Clinic > Articles by: admin

Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

By Global News Feed

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in two question and answer sessions at the H.C. Wainwright Virtual Precision Oncology Conference on Sept. 24.

View post:
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference

Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science

By Global News Feed

Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases Named a 2020 Tang Prize Laureate earlier this year, Feldmann will sit on the Masters’ forum alongside fellow recipients to discuss cytokine-targeting therapies for the treatment of inflammatory diseases

View original post here:
Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science

Tiziana Life Sciences plc: Publication of Research Note

By Global News Feed

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1

Go here to see the original:
Tiziana Life Sciences plc: Publication of Research Note

New incentive program for the Board of Directors of Orphazyme

By Global News Feed

Orphazyme A/SCompany announcement                                                                                       No. 53/2020                                                                                                          Company Registration No. 32266355

Continue reading here:
New incentive program for the Board of Directors of Orphazyme

Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

By Global News Feed

BALA CYNWYD, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Monday, September 21, 2020, at 1:40 p.m. EDT.

Original post:
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

By Global News Feed

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020.

Here is the original post:
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

→←